Answers are grounded in this paper and cite their sources.
Triple-negative breast cancer (TNBC) remains the most aggressive breast cancer subtype, with the poorest prognosis among all forms of breast cancer. FOXA1 is a well-known pioneer factor in luminal breast cancer, however, despite its vital role in this tumor subtype, detailed information about FOXA1 expression and function in TNBC is notably lacking. This gap highlights the importance of exploring whether FOXA1 plays different roles across breast cancer subtypes. Accordingly, the present study aimed to assess the independent prognostic value of FOXA1 expression in a well-characterized cohort of 283 women with TNBC, evaluating its association with progression-free survival (PFS), overall survival (OS), and distant metastasis, and to determine whether this association is independent of the systemic treatment received. Initial analyses employed chi-square and t-tests to identify associations, followed by multivariate logistic and Cox regression models to determine independent predictors. Survival analyses were performed using Kaplan-Meier curves, with comparisons made using the log-rank test. The median age of patients was 69 years. FOXA1 positivity was significantly associated with grade II tumors (p < 0.001) and Ki-67 levels lower than 20% (p < 0.001). In multivariate analysis, FOXA1 was shown to be a poor prognostic factor for PFS (HRa = 1.68; 95% CI: 1.13–2.48; p = 0.009). Furthermore, in treatment-adjusted models, FOXA1 expression remained as an independent predictor of poor PFS (HRa = 1.96; 95% CI: 1.29–2.98; p = 0.001). These findings establish FOXA1 as an independent prognostic biomarker for disease progression in TNBC, with its adverse impact on PFS persisting regardless of the chemotherapeutic regimen administered.
No takes yet. Share an insight, caveat, or question.
Fonseca-Benítez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: